Reduced Expression of PER3 Is Associated with Incidence and Development of Colon Cancer

详细信息    查看全文

• 作者：Xiaoliang Wang PhD (1)
  Dongwang Yan PhD (1)
  Mujian Teng PhD (2)
  Junwei Fan PhD (1)
  Chongzhi Zhou PhD (1)
  Dawei Li PhD (1)
  Guoqiang Qiu MD (1)
  Xing Sun PhD (1)
  Tao Li PhD (1)
  Tonghai Xing PhD (1)
  Huamei Tang MD (3)
  Xiao Peng MD (4)
  Zhihai Peng MD ; PhD ; FACS (1)
  
• 刊名：Annals of Surgical Oncology
• 出版年：2012
• 出版时间：September 2012
• 年：2012
• 卷：19
• 期：9
• 页码：3081-3088
• 全文大小：717KB
• 参考文献：1. Nelson RS, Thorson AG. Colorectal cancer screening. / Curr Oncol Rep. 2009;11:482-. CrossRef
  2. Labianca R, Beretta GD, Kildani B, et al. Colon cancer. / Crit Rev Oncol Hematol. 2010;74:106-3. CrossRef
  3. Li M, Gu J. Changing patterns of colorectal cancer in China over a period of 20?years. / World J Gastroenterol. 2005;11:4685-.
  4. Fan J, Peng Z, Zhou C, et al. Gene-expression profiling in Chinese patients with colon cancer by coupling experimental and bioinformatic genomewide gene-expression analyses: identification and validation of IFITM3 as a biomarker of early colon carcinogenesis. / Cancer. 2008;113:266-5. CrossRef
  5. Eriguchi M, Levi F, Hisa T, Yanagie H, Nonaka Y, Takeda Y. Chronotherapy for cancer. / Biomed Pharmacother. 2003;57:92?s-?s. CrossRef
  6. Archer SN, Robilliard DL, Skene DJ, et al. A length polymorphism in the circadian clock gene / Per3 is linked to delayed sleep phase syndrome and extreme diurnal preference. / Sleep. 2003;26:413-.
  7. Ebisawa T, Uchiyama M, Kajimura N, et al. Association of structural polymorphisms in the human period3 gene with delayed sleep phase syndrome. / EMBO Rep. 2001;2:342-. CrossRef
  8. Johansson C, Willeit M, Smedh C, et al. Circadian clock–related polymorphisms in seasonal affective disorder and their relevance to diurnal preference. / Neuropsychopharmacology. 2003;28:734-. CrossRef
  9. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG. Deregulated expression of the / PER1, PER2 and / PER3 genes in breast cancers. / Carcinogenesis. 2005;26:1241-. CrossRef
  10. Zhu Y, Brown HN, Zhang Y, Stevens RG, Zheng T. Period3 structural variation: a circadian biomarker associated with breast cancer in young women. / Cancer Epidemiol Biomarkers Prev. 2005;14:268-0.
  11. Lin YM, Chang JH, Yeh KT, et al. Disturbance of circadian gene expression in hepatocellular carcinoma. / Mol Carcinog. 2008;47:925-3. CrossRef
  12. Tokunaga H, Takebayashi Y, Utsunomiya H, et al. Clinicopathological significance of circadian rhythm–related gene expression levels in patients with epithelial ovarian cancer. / Acta Obstet Gynecol Scand. 2008;87:1060-0. CrossRef
  13. Zhu Y, Stevens RG, Hoffman AE, et al. Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. / Cancer Res. 2009;69:9315-2. CrossRef
  14. Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. / Nat Rev Cancer. 2003;3:350-1. CrossRef
  15. Yang MY, Chang JG, Lin PM, et al. Down-regulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of h / PER3. / Cancer Sci. 2006;97:1298-07. CrossRef
  16. Engstrom PF, Benson AB 3rd, Chen YJ, et al. Colon cancer clinical practice guidelines in oncology. / J Natl Compr Canc Netw. 2005;3:468-1.
  17. Li D, Yan D, Tang H, et al. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. / Ann Surg Oncol. 2009;16:3499-06. CrossRef
  18. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. / Nature. 2002;418:935-1. CrossRef
  19. Barnes JW, Tischkau SA, Barnes JA, et al. Requirement of mammalian Timeless for circadian rhythmicity. / Science. 2003;302:439-2. CrossRef
  20. Garceau NY, Liu Y, Loros JJ, Dunlap JC. Alternative initiation of translation and time-specific phosphorylation yield multiple forms of the essential clock protein frequency. / Cell. 1997;89:469-6. CrossRef
  21. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. / Science. 2003;302:255-. CrossRef
  22. Sahar S, Sassone-Corsi P. Metabolism and cancer: the circadian clock connection. / Nat Rev Cancer. 2009;9:886-6. CrossRef
  23. Shih HC, Choo KB, Chang TJ, et al. Disturbance of circadian gene expression in endometrial cancer: detection by real-time quantitative RT-PCR. / Oncol Rep. 2005;14:1533-.
  24. Im JS, Jung BH, Kim SE, Lee KH, Lee JK. / Per3, a circadian gene, is required for Chk2 activation in human cells. / FEBS Lett. 2010;584:4731-. CrossRef
  25. Keith LG, Oleszczuk JJ, Laguens M. Circadian rhythm chaos: a new breast cancer marker. / Int J Fertil Womens Med. 2001;46:238-7.
  
• 作者单位：Xiaoliang Wang PhD (1)
  Dongwang Yan PhD (1)
  Mujian Teng PhD (2)
  Junwei Fan PhD (1)
  Chongzhi Zhou PhD (1)
  Dawei Li PhD (1)
  Guoqiang Qiu MD (1)
  Xing Sun PhD (1)
  Tao Li PhD (1)
  Tonghai Xing PhD (1)
  Huamei Tang MD (3)
  Xiao Peng MD (4)
  Zhihai Peng MD, PhD, FACS (1)
  
  1. Department of General Surgery, Shanghai Jiao Tong University Affiliated First People’s Hospital, Shanghai, China
  2. Department of General Surgery, Shandong Provincial Qianfoshan Hospital of Shandong University, Jinan, China
  3. Department of Pathology, Shanghai Jiao Tong University Affiliated First People’s Hospital, Shanghai, China
  4. Department of Clinical Medicine, Xiangya School of Medicine, Central South University, Changsha, China
  

文摘

Background Period 3 (PER3), a circadian regulation protein, influences cell cycle, growth, and differentiation. The aim of the present study was to determine whether PER3 expression is associated with colon cancer incidence and progression. Methods PER3 expression was analyzed in the normal and cancerous tissues from patients with colon cancer by establishing a long serial analysis of gene expression (SAGE) database as well as by real-time PCR and immunohistochemistry. Results As compared with normal tissue, a 2.8-fold decrease in PER3 mRNA levels in colon cancerous tissue was observed. Real-time PCR analysis revealed that PER3 mRNA levels in tumor tissues were lower than in normal tissues (P?<?0.001) in both patients with colon tumor and those with rectal tumor. In addition, PER3 expression was related to multiple clinicopathologic factors, including tumor location, differentiation, and stage. Furthermore, the incidence of death was higher in subjects with PER3-negative tumors (P?=?0.025); the estimated overall survival time was 71.5?±?2.2?months and 58.6?±?5.0?months in subjects with PER3-positive and PER3-negative tumors, respectively (P?=?0.020). Conclusions PER3 may play a role in colon cancer progression.